IPILIMUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT IN EXTENSIVE DISEASE-SMALL CELL LUNG CANCER (ED-SCLC): RESULTS FROM A PHASE 2 TRIAL

被引：0
|
作者：
Reck, Martin [1 ]
Bondarenko, Igor [2 ]
Luft, Alexander [3 ]
Serwatowski, Piotr
Barlesi, Fabrice [4 ]
Chacko, Raju [5 ]
Sebastian, Martin [6 ]
Siegel, Jonathan [7 ]
Cuillerot, Jean-Marie [7 ]
Lynch, Thomas [8 ,9 ]
机构：
[1] Hosp Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany
[2] City Clin Hosp, Kiev, Ukraine
[3] Leningrad Reg Clin Hosp, St Petersburg, Russia
[4] Univ Aix Marseille 2, Assistance Publ Hop Marseille, Marseille, France
[5] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[6] Johannes Gutenberg Univ Med Ctr, Dept Hematol Oncol & Pneumol, Mainz, Germany
[7] Bristol Myers Squibb Co, New York, NY 10154 USA
[8] Yale Canc Ctr, Dept Oncol, New Haven, CT USA
[9] Smilow Canc Hosp, New Haven, CT USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S310 / S311
页数：2
相关论文
共 50 条
  • [31] Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
    Arriola, Edurne
    Wheater, Matthew
    Galea, Ian
    Cross, Nadia
    Maishman, Tom
    Hamid, Debbie
    Stanton, Louise
    Cave, Judith
    Geldart, Tom
    Mulatero, Clive
    Potter, Vannessa
    Danson, Sarah
    Woll, Pennella J.
    Griffiths, Richard
    Nolan, Luke
    Ottensmeier, Christian
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (09) : 1511 - 1521
  • [32] Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC)
    Cho, B. C.
    Dy, G. K.
    Govindan, R.
    Kim, D. W.
    Pennell, N. A.
    Zalcman, G.
    Besse, B.
    Nogai, H.
    Rajagopalan, P.
    Ocker, M.
    Barlesi, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S634 - S634
  • [33] Current standards and promising innovations in second-line drug therapy of extensive disease small cell lung cancer (ED-SCLC)
    Pogorzelski, Michael
    Schuler, Martin
    ONKOLOGIE, 2024, 30 (09): : 809 - 816
  • [34] Randomized phase 2 study of carboplatin plus irinotecan (CI) versus carboplatin plus amrubicin (CA) for extensive disease small-cell lung cancer (ED-SCLC): NJLCG0901.
    Kawashima, Yosuke
    Morikawa, Naoto
    Sugawara, Shunichi
    Maemondo, Makoto
    Harada, Toshiyuki
    Harada, Masao
    Inoue, Akira
    Fujita, Yuka
    Kato, Terufumi
    Yokouchi, Hiroshi
    Watanabe, Hiroshi
    Usui, Kazuhiro
    Suzuki, Toshiro
    Oizumi, Satoshi
    Nagai, Hiroki
    Kanbe, Mariko
    Nukiwa, Toshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] THE EFFECT OF PROPHYLACTIC CRANIAL IRRADIATION (PCI) IN THE PATIENTS WITH EXTENSIVE-DISEASE SMALL-CELL LUNG CANCER (ED-SCLC): RESULTS OF A JAPANESE RANDOMIZED PHASE III TRIAL
    Naito, T.
    Takahashi, T.
    Yamanaka, T.
    Harada, H.
    Seto, T.
    Satouchi, M.
    Oizumi, S.
    Katakami, N.
    Shibata, K.
    Maemondo, M.
    Kiura, K.
    Okamoto, H.
    Minato, K.
    Yamamoto, N.
    ANNALS OF ONCOLOGY, 2014, 25
  • [36] Real-world analysis of outcomes of first- line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC)
    Zellweger, N.
    Schmid, S.
    Bertschinger, M.
    Waibel, C.
    Cerciello, F.
    Frosch, P.
    Mark, M.
    Bettini, A.
    Hauptle, P.
    Blum, V.
    Litke, T.
    Fruh, M.
    Mauti, L.
    Rothschild, S.
    SWISS MEDICAL WEEKLY, 2022, 152 : 47S - 48S
  • [37] A phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) that is refractory or progressive within 90 days of completion of first-line platinum-based chemotherapy
    Ettinger, D. S.
    Jotte, R. M.
    Gupta, V.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Phase I study of paclitaxel and topotecan for the first-line treatment of extensive-stage small cell lung cancer
    West, W
    Birch, R
    Schnell, F
    Hainsworth, J
    Tongol, J
    Campos, L
    ONCOLOGIST, 2003, 8 (01): : 76 - 82
  • [39] Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line stage IIIb/IV non-small cell lung cancer (NSCLC).
    Lynch, T. J.
    Bondarenko, I. N.
    Luft, A.
    Serwatowski, P.
    Barlesi, F.
    Chacko, R. T.
    Sebastian, M.
    Siegel, J.
    Cuillerot, J.
    Reck, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Phase II trial of gemcitabine, carboplatin and vindesine in extensive disease stage I/II small cell lung cancer (ED I/II SCLC).
    Faderl, B
    von Pawel, J
    ANNALS OF ONCOLOGY, 2000, 11 : 113 - 113
12345